SNA-based therapy increases SMA survival four-fold over standard of care

A new investigational treatment for spinal muscular atrophy, utilizing spherical nucleic acids (SNAs) developed by IIN Director Chad Mirkin and the Mirkin Research Group, prolongs survival–four times longer than the current standard of care–with limited toxicity, according to a new Ohio State research study. Read more.